CROI 2023 – progress on efforts to cure HIV
Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
Nimbus hopes to strike thrice
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
Astrazeneca gets personal
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
Ash 2022 – Orchard gets a Sanfilippo boost
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
Amgen tries something new in obesity
Early data are promising, but the upcoming phase 2 trial has questions to answer.
